Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

Menin inhibitors are novel targeted agents currently in clinical development for the treatment
of genetically defined subsets of acute leukemia. Menin has a tumor suppressor function in …

Novel drugs, drug sequences and combinations have improved the outcome of prostate
cancer in recent years. The latest approvals include abiraterone acetate, enzalutamide and …

Photodynamic therapy is an effective alternative to traditional treatments due to its minimally
invasive nature, negligible systemic toxicity, fewer side effects, and avoidance of drug …

Prostate cancer represents a substantial clinical challenge because it is difficult to predict
outcome and advanced disease is often fatal. We sequenced the whole genomes of 112 …

The development and immune evasion of cancer stem cells (CSCs) limit the efficacy of
currently available anticancer therapies. Recent studies have shown that epigenetic …

Highlights•Patients who receive antiandrogen treatments are more likely to develop
CRPC.•A genomic landscape study has identified aberrant epigenetic events in CRPC and …

A drug must engage its intended target to achieve its therapeutic effect. However,
conclusively measuring target engagement (TE) in situ is challenging. This complicates …

The androgen receptor (AR) is overexpressed and hyperactivated in human castration-
resistant prostate cancer (CRPC). However, the determinants of AR overexpression in …

The PI3-kinase/AKT pathway integrates signals from external cellular stimuli to regulate
essential cellular functions, and is frequently aberrantly activated in human cancers. Recent …